Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YAP1 | P46937 | 3/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | CACNB4 | O00305 | 2/20 | 0.42 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.42 |
| ▸ | CACNG3 | O60359 | 2/20 | 0.42 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.42 |
| ▸ | CACNB3 | P54284 | 2/20 | 0.42 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.42 |
| ▸ | CACNG7 | P62955 | 2/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.42 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.42 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.42 |
| ▸ | CACNG1 | Q06432 | 2/20 | 0.42 |
| ▸ | CACNB2 | Q08289 | 2/20 | 0.42 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3281890 | 0.86 | EGFR (0.52) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL3276980 | 0.84 | PRMT5 (0.47) | YAP1PRMT5GPR119PDE4APDE4B | |
| SCHEMBL3274950 | 0.84 | HTR2C (0.53) | EGFR | |
| SCHEMBL3280041 | 0.81 | GPR119 (0.48) | GPR119EGFRPDE4APDE4BPDE4C | |
| SCHEMBL3282210 | 0.81 | KDM1A (0.50) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| Hydrochloric Acid SCHEMBL3275712 | 0.81 | SRC (0.61) | EGFR | |
| SCHEMBL2195527 | 0.80 | PDE4A (0.53) | YAP1PRMT5GPR119PDE4APDE4B | |
| SCHEMBL3166578 | 0.79 | YAP1 (0.54) | YAP1PRMT5GPR119PDE4APDE4B | |
| SCHEMBL3276703 | 0.78 | EGFR (0.47) | EGFR | |
| SCHEMBL76105 | 0.78 | YAP1 (0.60) | YAP1PRMT5GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280042-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | HENNEQUIN LAURENT FRANCOIS ANDRE | 2010-11-04 | — | — | US | disclosed |
| US-7696214-B2 | Quinazoline derivatives for the treatment of tumours | ASTRAZENECA AB (SE) | 2010-04-13 | — | — | US | disclosed |
| US-7160891-B2 | Quinazoline derivatives for the treatment of T cell mediated diseases | ASTRAZENECA AB (SE) | 2007-01-09 | — | — | US | disclosed |
| US-20060258642-A1 | Quinazoline derivatives for the treatment of tumours | ASTRAZENECA AB | 2006-11-16 | — | — | US | disclosed |
| US-7049438-B2 | Quinazoline derivatives for treatment of tumours | ASTRAZENECA AB (SE) | 2006-05-23 | — | — | US | disclosed |
| EP-1450808-B8 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2006-01-04 | — | — | EP | disclosed |
| US-20050038050-A1 | Quinazoline derivatives for the treatment of t cell mediated diseases | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | US | disclosed |
| US-20040214841-A1 | Quinazoline derivatives for treatment of tumours | ASTRAZENECA AB (SE) | 2004-10-28 | — | — | US | disclosed |
| EP-1450808-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | Astrazeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003045395-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | disclosed |
| WO-2001094341-A9 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2003-04-17 | — | — | WO | disclosed |
| EP-1292594-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | AstraZeneca AB (SE) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001094341-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258642-A1 | Quinazoline derivatives for the treatment of tumours | TPD52L2, NQO2, H1-5 | YAP1 3089/4885PRMT5 201/4885TLR9 3404/4885 |
| US-20040214841-A1 | Quinazoline derivatives for treatment of tumours | NQO2, TOP1, TPD52L2 | YAP1 4393/4885PRMT5 194/4885TLR9 2714/4885 |
| US-20050038050-A1 | Quinazoline derivatives for the treatment of t cell mediated diseases | CD4, HLA-DRB1, IFNG | YAP1 4790/4885PRMT5 108/4885TLR9 351/4885 |
| US-20100280042-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | TPD52L2, NQO2, H1-5 | YAP1 3089/4885PRMT5 201/4885TLR9 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.